XmAb541: A Selectivity Engineered XmAb 2+1 CLDN6 x CD3 Bispecific Antibody for Treatment of Ovarian Cancer & Other CLDN6+ Solid Tumors
Time: 1:30 pm
day: Day One
Details:
- Xencor’s XmAb® platforms allow for the rapid development of therapeutic bispecific with novel formats/binding modes that engage T cells (xCD3, xCD28) or NK cells xNKp46, xNKG2D) or act though other mechanisms in oncology, autoimmune, and inflammatory disorders.
- Analysis of genomic/transcriptomic data to identify CLDN6 as an antigen with high expression in ovarian cancer tumors with very little expression in normal tissues & overcoming binding selectivity requirements as other similar CLDNs are expressed in normal tissue.
- Target selection and preclinical development of XmAb541, a CLDN6xCD3 2+1 bispecific protein for treating patients with ovarian cancer and other solid tumor indications.
